Why Moderna Shares Dipped On Tuesday

Moderna MRNA shares are trading lower on reports suggesting the company is having supply issues.

According to a Reuters report, the company said that it does not have a sufficient stock of vaccines in storage to smooth shortfalls or delays and said the current delay can lead to short-term adjusting in the coming 2-4 weeks. 

Moderna is a biotechnology company that develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. As of March 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities. 

At the time of publication, shares of Moderna were trading 2.9% at lower at $326.29. The stock has a 52-week low of $54.21 and a 52-week high of $362. 

See also: How to Buy Moderna MRNA Stock 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideas'why it's moving'
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!